MIL62 Plus Lenalidomide for Patients With Relapsed/Refractory Indolent Non-Hodgkin's Lymphoma (FL and MZL)
A phase 1/2 trial of Lenalidomide in follicular lymphoma, run by Beijing Mabworks Biotech Co., Ltd., now recruiting.
Overview
MIL62 Plus Lenalidomide for Patients With Relapsed/Refractory Indolent Non-Hodgkin's Lymphoma (FL and MZL) is a phase 1/2 interventional study registered as NCT04110301 by Beijing Mabworks Biotech Co., Ltd., with 53 participants planned, started 2019-11-28 and due to reach its primary completion in 2024-01-09. Interventions recorded: Recombinant Humanized Monoclonal Antibody MIL62 Injection, Lenalidomide. Conditions listed: Follicular Lymphoma and Marginal Zone Lymphoma. No results are recorded here; the registry entry is the source.
Similar pages
not linked directly; found by shared links- TrialMIL62 Combined With Lenalidomide Versus Lenalidomide for Patients With Rituximab Refractory Follicular Lymphoma
- TrialA Novel Vaccine (EO2463) as Monotherapy and in Combination, for Treatment of Patients With Indolent Non-Hodgkin Lymphoma
Shares Lenalidomide, Follicular lymphoma.
- TrialA Study Evaluating the Efficacy and Safety of Mosunetuzumab in Combination With Lenalidomide in Comparison to Rituximab in Combination With Lenalidomi
Shares Lenalidomide, Follicular lymphoma.
- TrialStudy of Subcutaneous Epcoritamab in Combination With Intravenous Rituximab and Oral Lenalidomide (R2) to Assess Adverse Events and Change in Disease
Shares Lenalidomide, Follicular lymphoma.
- TrialA Trial to Find Out if Odronextamab Combined With Lenalidomide is Safe and Works Better Than Rituximab Combined With Lenalidomide in Adult Participant
Shares Lenalidomide, Follicular lymphoma.
- TrialA Phase 3 Study to Assess Efficacy and Safety of Tafasitamab Plus Lenalidomide and Rituximab Compared to Placebo Plus Lenalidomide and Rituximab in Pa
Shares Lenalidomide, Follicular lymphoma.
- TrialA Study Evaluating the Safety, Pharmacokinetics, and Efficacy of Mosunetuzumab + Lenalidomide (+Len), and the Safety, Tolerability, and Pharmacokineti
Shares Lenalidomide, Follicular lymphoma.
- TrialA Study to Assess the Efficacy, Safety, Pharmacodynamics, and Pharmacokinetics of Tazemetostat in Combination With Lenalidomide Plus Rituximab Versus
Shares Lenalidomide, Follicular lymphoma.